Anybody with cancer. For patients with hematologic malignancies (blood cancers) and soft tissue sarcomas, sequencing can be used early at diagnosis, for prognostication, and to guide overall clinical management. Folks with solid tumors (i.e. prostate, breast, lung, pancreatic, etc) become eligible when they have more advanced disease – and they should absolutely demand it when they become stage III/IV. Unfortunately, more than 60 percent of advanced cancer patients today receive no genomic testing — and are often relegated to highly toxic and ineffective therapies. Let’s change that!